Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed neuroendocrine tumor OR characteristic radiological findings of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of the following criteria:
• * Primary disease in gut with liver metastases (with or without hormone secretion)
• * Primary disease in lung with liver or abdominal metastases (with or without hormone secretion)
• * Primary disease in pancreas with or without metastases (with or without hormone secretion)
• PATIENT CHARACTERISTICS:
• Any Karnofsky performance status allowed
• Life expectancy ≥ 3 months
• Able to understand the questionnaire language
• Mentally fit to complete questionnaire
• No psychological, familial, sociological, or geographical condition that would limit study compliance
• No other concurrent malignancies except basal cell carcinoma of the skin
• PRIOR CONCURRENT THERAPY:
• More than 2 months since prior somatostatin analogue or interferon therapy (somatostatin therapy stratum)
• * Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable over the past month
• More than 6 months since prior radionuclide therapy or systemic chemotherapy (radionuclide or systemic chemotherapy stratum)
• More than 6 months since prior ablative therapies (ablative therapy stratum)
• No concurrent participation in other quality of life studies